CAPRIN-1 Targeting Antibody for Selective Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using antibodies targeting cancer antigens often result in adverse reactions due to the expression of these antigens in both cancer and normal cells, leading to insufficient therapeutic outcomes and increased side effects.
Innovation Solution
Development of an antibody specifically targeting a partial CAPRIN-1 polypeptide, which is predominantly expressed on cancer cells, utilizing monoclonal or polyclonal antibodies, including human, humanized, chimeric, or single-chain antibodies, to enhance antitumor activity while minimizing damage to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibodies targeting cancer antigens are used, then cancer cells can be targeted, but normal cells are also damaged due to antigen expression in both cancer and normal cells, resulting in adverse reactions
Solution Approach 1:
The patent applies local quality by developing an antibody that specifically recognizes and binds to CAPRIN-1 protein expressed on cancer cell surfaces, while not binding to normal cells. This selective binding capability creates localized therapeutic action at the cancer site without affecting normal tissues, thereby resolving the contradiction between cancer targeting efficacy and adverse reactions from normal cell damage
Solution Approach 2:
The patent segments the target population by identifying a specific biomarker (CAPRIN-1) that is differentially expressed between cancer and normal cells. By targeting this segmented marker rather than general cancer antigens, the therapy can distinguish between cancer and normal cells, achieving high efficacy while minimizing off-target effects
2Adaptability or versatility
If antibodies targeting widely expressed cancer antigens are used, then broad cancer coverage is achieved, but specificity is reduced leading to increased side effects
Solution Approach 1:
The patent changes the selection parameter from general cancer antigens to a specific molecular marker (CAPRIN-1) with distinct expression patterns. This parameter change enables the antibody to maintain broad adaptability across different cancer types that express CAPRIN-1 while achieving high manufacturing precision through specific molecular recognition, thereby resolving the contradiction between broad coverage and targeting specificity
Data Source
AI summary
The invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the antibody or fragment thereof as an active ingredient.